Protagonist, Takeda announces Phase 3 VERIFY study met primary endpoint

Protagonist Therapeutics (PTGX) and Takeda (TAK) announced detailed results from the Phase 3, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera, which met the primary and all key secondary endpoints. The data will be presented as a late-breaking oral presentation at the 61st American Society of Clinical Oncology, ASCO, Annual Meeting Plenary Session. The study met its primary endpoint, which was the proportion of patients achieving a clinical response, defined as the absence of phlebotomy eligibility during study Weeks 20-32. Study results demonstrated 76.9% of patients treated with rusfertide plus current standard of care achieved a clinical response, compared to 32.9% in the placebo plus current standard of care group. The response observed in the rusfertide arm was consistent across subgroups, regardless of risk status or type of concurrent cytoreductive therapy. In addition, all key secondary endpoints met statistical significance in favor of the rusfertide arm compared to the placebo arm in the VERIFY study.
Confident Investing Starts Here:

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

a day ago

• Yahoo

Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is one of the 10 biotech stocks screaming a buy. On June 17, Citi initiated coverage of the stock with a 'Buy' rating and a $72 price target. The research firm remains bullish about the company's prospects owing to the strong potential of its drug candidates. A scientist in a lab coat examining a Petri dish containing a biopharmaceutical culture. The company's partnership with Takeda on Rusfertide to treat polycythemia Vera (PV) and oral IL-23 (icotrokinra) is one of the developments that underscore the research firm's favorable rating. Rusfertide demonstrated strong potential in PV patients in phase 3 trials, affirming its potential to address unmet needs. Citi is especially bullish about adding Rusfertide to existing therapies to expand its use case. In addition, the firm echoed the company's strategic partnership with Johnson & Johnson for multiple inflammation indications. According to Citi, Protagonist Therapeutics shares have outperformed over the past three months, going up by a 40% gain compared to a 2% gain of the S&P 500. It expects the company's combined revenues to climb to $700 million by 2032, above consensus estimates of $680 million. Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a biopharmaceutical company that develops peptide-based drugs to treat various diseases, including rare and prevalent ones. Its pipeline includes treatments for blood disorders like polycythemia Vera and inflammatory conditions like ulcerative colitis and psoriasis. While we acknowledge the potential of PTGX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Business Upturn

3 days ago

• Business Upturn

Labviva Showcases Advanced AI Procurement Tools at the R&D Procurement and Sourcing in Pharma Summit 2025

BOSTON, June 19, 2025 (GLOBE NEWSWIRE) — Labviva, the leading AI procurement platform for life sciences, today announced its plans to demonstrate how pharmaceutical and biotech companies can leverage AI for laboratory procurement to drive cost and resource efficiencies and accelerate the pace of scientific innovation. The company will showcase its purchasing platform and inventory management solution (IMS) and plans to debut a new AI solution at the R&D Procurement & Sourcing in Pharma Summit, located at the Hilton Boston Logan Airport on June 24-26. Co-presenting panel on 'Modernizing Inventory Management: How Neutral Models Are Enabling Smarter Lab Operations' This panel will focus on lessons learned, change leadership, and value delivered through a vendor-neutral approach to inventory management. It will also highlight: How Takeda modernized its lab supply strategy with a vendor-agnostic, data-driven approach to inventory management How a neutral model improved visibility, reduced waste, and gave Takeda more control over their supply needs How Boston Lab Services and Labviva partnered to deliver automation, flexibility, and operational excellence Actionable insights for transforming procurement from a cost center into a strategic R&D enabler The talk will take place at the R&D Procurement & Sourcing in Pharma Summit at 10:00 a.m. on June 26. It will be moderated by Kleida Martiro, Partner at Glasswing Ventures and panelists include Hillary Ferrer, R&D Operations at Takeda, Andrew Petterelli, Procurement at Takeda, Elden Lainez, CEO of Boston Lab Services and Nick Rioux, CTO of Labviva. Labviva's R&D Procurement Cocktail Reception Show attendees and members of the press can RSVP for Labviva's cocktail event which takes place at the Hilton Boston Logan Airport, One Hotel Dr, Boston, MA 02128, on June 24th from 5:00pm-6:00pm. 'At the R&D Procurement & Sourcing in Pharma Summit, we plan to demonstrate the value of modernizing research procurement processes using AI automation,' said Siamak Baharloo, CEO of Labviva. 'In an era of tariffs and trade wars, compliance and efficiency are king. And with Labviva, pharmaceutical procurement teams enjoy improved transparency, diverse supplier access, broad product and pricing options, and the inventory controls they need to ensure compliance, supply chain security, and mass efficiencies while maintaining complete control of their data.' To schedule a meeting or press interview with Labviva, please contact Jennifer Olszewski at [email protected] About Labviva Labviva connects researchers with suppliers of reagents, chemicals, and instrumentation in an intuitive, user-friendly platform that supports the priorities of scientists while staying compliant with purchasing rules. Suppliers can easily manage the content of their products, and products are mapped into scientific applications, techniques and protocols. To learn more about how Labviva accelerates the science of life, visit us at Media Contacts:Jennifer OlszewskiLabviva917-445-4454 [email protected]

Yahoo

3 days ago

• Yahoo

Labviva Showcases Advanced AI Procurement Tools at the R&D Procurement and Sourcing in Pharma Summit 2025

Global leader in source-to-pay solutions for life sciences to showcase an array of automated procurement technologies Labviva at R&D Procurement & Sourcing in Pharma Summit BOSTON, June 19, 2025 (GLOBE NEWSWIRE) -- Labviva, the leading AI procurement platform for life sciences, today announced its plans to demonstrate how pharmaceutical and biotech companies can leverage AI for laboratory procurement to drive cost and resource efficiencies and accelerate the pace of scientific innovation. The company will showcase its purchasing platform and inventory management solution (IMS) and plans to debut a new AI solution at the R&D Procurement & Sourcing in Pharma Summit, located at the Hilton Boston Logan Airport on June 24-26. Co-presenting panel on 'Modernizing Inventory Management: How Neutral Models Are Enabling Smarter Lab Operations' This panel will focus on lessons learned, change leadership, and value delivered through a vendor-neutral approach to inventory management. It will also highlight: How Takeda modernized its lab supply strategy with a vendor-agnostic, data-driven approach to inventory management How a neutral model improved visibility, reduced waste, and gave Takeda more control over their supply needs How Boston Lab Services and Labviva partnered to deliver automation, flexibility, and operational excellence Actionable insights for transforming procurement from a cost center into a strategic R&D enabler The talk will take place at the R&D Procurement & Sourcing in Pharma Summit at 10:00 a.m. on June 26. It will be moderated by Kleida Martiro, Partner at Glasswing Ventures and panelists include Hillary Ferrer, R&D Operations at Takeda, Andrew Petterelli, Procurement at Takeda, Elden Lainez, CEO of Boston Lab Services and Nick Rioux, CTO of Labviva. Labviva's R&D Procurement Cocktail Reception Show attendees and members of the press can RSVP for Labviva's cocktail event which takes place at the Hilton Boston Logan Airport, One Hotel Dr, Boston, MA 02128, on June 24th from 5:00pm-6:00pm. 'At the R&D Procurement & Sourcing in Pharma Summit, we plan to demonstrate the value of modernizing research procurement processes using AI automation,' said Siamak Baharloo, CEO of Labviva. 'In an era of tariffs and trade wars, compliance and efficiency are king. And with Labviva, pharmaceutical procurement teams enjoy improved transparency, diverse supplier access, broad product and pricing options, and the inventory controls they need to ensure compliance, supply chain security, and mass efficiencies while maintaining complete control of their data.' To schedule a meeting or press interview with Labviva, please contact Jennifer Olszewski at jolszewski@ About LabvivaLabviva connects researchers with suppliers of reagents, chemicals, and instrumentation in an intuitive, user-friendly platform that supports the priorities of scientists while staying compliant with purchasing rules. Suppliers can easily manage the content of their products, and products are mapped into scientific applications, techniques and protocols. To learn more about how Labviva accelerates the science of life, visit us at Media Contacts:Jennifer OlszewskiLabviva917-445-4454jolszewski@ or Michael IngallsPenVine for Labviva917-494-4909michael@ A photo accompanying this announcement is available at in to access your portfolio